TriSalus Life Sciences Inc expected to post a loss of 22 cents a share - Earnings Preview

TriSalus Life Sciences

13/05/2025 15:34

TriSalus Life Sciences Inc TLSI.OQ TLSI.O is expected to show a rise in quarterly revenue when it reports  results on May 15 for the period ending March 31 2025

The Westminster Colorado-based  company is expected to report a 39.9% increase in revenue to $9.036 million from $6.46 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for TriSalus Life Sciences Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 2.0% in the last three months. ​

Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $11.00​, above​ its last closing price of $5.11. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.34
-0.32
-0.40
Missed
-26
Sep. 30 2024
-0.35
-0.35
-0.12
Beat
65.3
Jun. 30 2024
-0.49
-0.49
-0.21
Beat
57.4​
Mar. 31 2024
-0.58
-0.65
-0.60
Beat
7.7
​​Dec. 31 2023
-0.69
-0.69
-1.56
Missed
-126.1
​

This summary was machine generated May 13 at 14:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)